PMID- 36715018
OWN - NLM
STAT- MEDLINE
DCOM- 20230323
LR  - 20231106
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 19
IP  - 1
DP  - 2023 Dec 31
TI  - Immune checkpoint inhibitors as first-line therapy for non-small cell lung 
      cancer: A systematic evaluation and meta-analysis.
PG  - 2169531
LID - 10.1080/21645515.2023.2169531 [doi]
LID - 2169531
AB  - Recently, immune checkpoint inhibitors (ICIs) present promising application 
      prospects in treating non-small cell lung cancer (NSCLC). This study aimed to 
      investigate optimal treatment strategy by comparing the first-line treatment 
      strategies with ICIs in NSCLC. We retrieved relevant studies on first-line 
      therapy of NSCLC with ICIs. Primary outcomes were overall survival (OS) and 
      progression-free survival (PFS). Secondary outcomes were treatment-related 
      serious adverse events (tr-SAEs) with grade 3 or higher and objective response 
      rate (ORR). We also conducted a Bayesian network meta-analysis. We included 14 
      studies involving 7,823 patients and compared seven different interventions. In 
      PD-L1 nonselective NSCLC, nivolumab+ipilimumab had good PFS and ORR, 
      pembrolizumab significantly prolonged OS, and nivolumab had the fewest adverse 
      events (AEs). For PD-L1-positive patients, nivolumab remarkably prolonged OS. For 
      those with negative PD-L1, nivolumab+ipilimumab also showed an advantage. In 
      addition, nivolumab+ipilimumab significantly prolonged the PFS in both 
      PD-L1-negative and -positive patients. For patients with PD-L1 tumor proportion 
      score (TPS) within 1-49%, atezolizumab+chemotherapy remarkably prolonged PFS and 
      OS. For those with PD-L1 TPS >/=50%, pembrolizumab prolonged OS and 
      atezolizumab+chemotherapy significantly prolonged PFS. Nivolumab combined with 
      ipilimumab showed advantages in OS, PFS and ORR in most patients. 
      Nivolumab+ipilimumab may be the optimal first-line therapy for NSCLC.
FAU - Lu, Yu
AU  - Lu Y
AD  - Department of General Practice, the First Affiliated Hospital, Hengyang Medical 
      School, University of South China, Hengyang, China.
FAU - Zhang, Xiaoyan
AU  - Zhang X
AD  - Department of General Practice, the First Affiliated Hospital, Hengyang Medical 
      School, University of South China, Hengyang, China.
FAU - Ning, Jiyu
AU  - Ning J
AD  - Department of General Practice, the First Affiliated Hospital, Hengyang Medical 
      School, University of South China, Hengyang, China.
FAU - Zhang, Manyan
AU  - Zhang M
AD  - Department of Respiration, the First Affiliated Hospital, Hengyang Medical 
      School, University of South China, Hengyang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20230130
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 31YO63LBSN (Nivolumab)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Nivolumab/therapeutic use
MH  - *Lung Neoplasms/drug therapy
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - B7-H1 Antigen
MH  - Ipilimumab/therapeutic use
MH  - Bayes Theorem
PMC - PMC10038046
OTO - NOTNLM
OT  - NSCLC
OT  - chemotherapy
OT  - first-line therapy
OT  - immune checkpoint inhibitor
OT  - network meta-analysis
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2023/01/31 06:00
MHDA- 2023/03/24 06:00
PMCR- 2023/01/30
CRDT- 2023/01/30 05:03
PHST- 2023/01/31 06:00 [pubmed]
PHST- 2023/03/24 06:00 [medline]
PHST- 2023/01/30 05:03 [entrez]
PHST- 2023/01/30 00:00 [pmc-release]
AID - 2169531 [pii]
AID - 10.1080/21645515.2023.2169531 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2023 Dec 31;19(1):2169531. doi: 
      10.1080/21645515.2023.2169531. Epub 2023 Jan 30.